Log in

Bausch Health Companies Stock Price, Forecast & Analysis (NYSE:BHC)

$28.48
+0.73 (+2.63 %)
(As of 11/17/2019 06:06 AM ET)
Today's Range
$27.83
Now: $28.48
$28.64
50-Day Range
$19.10
MA: $22.98
$28.55
52-Week Range
$17.20
Now: $28.48
$28.64
Volume5.05 million shs
Average Volume4.13 million shs
Market Capitalization$10.02 billion
P/E Ratio7.08
Dividend YieldN/A
Beta0.87
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone514-744-6792

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.38 billion
Cash Flow$12.66 per share
Book Value$7.28 per share

Profitability

Net Income$-4,148,000,000.00

Miscellaneous

Employees21,100
Market Cap$10.02 billion
Next Earnings Date2/19/2020 (Estimated)
OptionableOptionable

Receive BHC News and Ratings via Email

Sign-up to receive the latest news and ratings for BHC and its competitors with MarketBeat's FREE daily newsletter.


Bausch Health Companies (NYSE:BHC) Frequently Asked Questions

What is Bausch Health Companies' stock symbol?

Bausch Health Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHC."

How were Bausch Health Companies' earnings last quarter?

Bausch Health Companies Inc (NYSE:BHC) posted its earnings results on Tuesday, August, 7th. The company reported $0.93 EPS for the quarter, beating the Zacks' consensus estimate of $0.81 by $0.12. The company had revenue of $2.13 billion for the quarter, compared to the consensus estimate of $2.05 billion. Bausch Health Companies had a positive return on equity of 56.19% and a negative net margin of 7.25%. View Bausch Health Companies' Earnings History.

When is Bausch Health Companies' next earnings date?

Bausch Health Companies is scheduled to release their next quarterly earnings announcement on Wednesday, February 19th 2020. View Earnings Estimates for Bausch Health Companies.

What price target have analysts set for BHC?

15 Wall Street analysts have issued 1-year target prices for Bausch Health Companies' shares. Their forecasts range from $9.00 to $54.00. On average, they expect Bausch Health Companies' share price to reach $30.56 in the next year. This suggests a possible upside of 7.3% from the stock's current price. View Analyst Price Targets for Bausch Health Companies.

What is the consensus analysts' recommendation for Bausch Health Companies?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last year. There are currently 2 sell ratings, 1 hold rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bausch Health Companies.

What are Wall Street analysts saying about Bausch Health Companies stock?

Here are some recent quotes from research analysts about Bausch Health Companies stock:
  • 1. According to Zacks Investment Research, "Bausch beat both earnings and sales estimates in the third quarter and raised annual guidance. Both the Bausch + Lomb/International and Salix segments drove the quarterly performance on higher revenues in several established brands, such as Xifaxan, BioTrue ONEday and Bausch + Lomb ULTRA. Newer products, such as Lumify and Thermage FLX, also performed well. The initial uptake of psoriasis lotion, Duobrii, has been encouraging as well. After a tumultuous period, the company started a rebuilding process. Bausch has narrowed its focus on seven products — Vyzulta, Siliq, Bryhali, Lumify, Duobrii, Relistor and SiHy Daily. These have now been launched and hence the company’s performance is expected to be strong. However, the dermatology market continues to be challenging. Shares have outperformed the industry in the year so far." (11/6/2019)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks, and uncertainties. We employ a cash EPS multiple-based approach. The cash EPS number is derived from our adjusted 12-month income, which employs a total 12-month adjusted (non-GAAP) income projection of roughly $1.6B, which we divide by approximately 357M shares outstanding to derive our 12-month cash EPS of $4.46 per share." (8/7/2019)
  • 3. Cantor Fitzgerald analysts commented, "We rate BHC as 12-month price target of $32. A greater appreciation for BHC’s solid execution and future growth prospects under the new management team should drive upwards earnings revisions in 2019+, multiple expansion, and BHC shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $32." (4/25/2019)

Has Bausch Health Companies been receiving favorable news coverage?

Media headlines about BHC stock have been trending somewhat negative on Sunday, InfoTrie reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bausch Health Companies earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Bausch Health Companies.

Are investors shorting Bausch Health Companies?

Bausch Health Companies saw a decrease in short interest in October. As of October 31st, there was short interest totalling 9,760,000 shares, a decrease of 17.9% from the September 30th total of 11,890,000 shares. Based on an average daily trading volume, of 3,580,000 shares, the days-to-cover ratio is presently 2.7 days. Approximately 2.8% of the company's shares are sold short. View Bausch Health Companies' Current Options Chain.

Who are some of Bausch Health Companies' key competitors?

What other stocks do shareholders of Bausch Health Companies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Constellation Software (CSU), Intact Financial (IFC), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), Twitter (TWTR), Bank of America (BAC), NVIDIA (NVDA) and Tesla (TSLA).

Who are Bausch Health Companies' key executives?

Bausch Health Companies' management team includes the folowing people:
  • Mr. Joseph C. Papa, CEO & Chairman (Age 64)
  • Mr. Paul S. Herendeen, Exec. VP & CFO (Age 63)
  • Mr. Thomas J. Appio, Pres & Co-Head Bausch + Lomb/International (Age 57)
  • Mr. William D. Humphries, Pres of Ortho-Dermatologics (Age 53)
  • Mr. Osama A. Eldessouky, Sr. VP, Controller & Chief Accounting Officer (Age 47)

Who are Bausch Health Companies' major shareholders?

Bausch Health Companies' stock is owned by a number of of institutional and retail investors. Top institutional investors include Ardevora Asset Management LLP (0.54%), Alberta Investment Management Corp (0.39%), Commerzbank Aktiengesellschaft FI (0.30%), Sumitomo Mitsui Trust Holdings Inc. (0.21%), Academy Capital Management Inc. TX (0.20%) and Terril Brothers Inc. (0.14%). Company insiders that own Bausch Health Companies stock include Christina Ackermann, John Paulson, Joseph C Papa, Mark C Mckenna, Paul Herendeen, Schutter Richard U De, Thomas Appio and William D Humphries. View Institutional Ownership Trends for Bausch Health Companies.

Which major investors are selling Bausch Health Companies stock?

BHC stock was sold by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank, Daiwa Securities Group Inc., Systematic Financial Management LP, Terril Brothers Inc., Russell Investments Group Ltd., Crossmark Global Holdings Inc., Gulf International Bank UK Ltd and SeaCrest Wealth Management LLC. Company insiders that have sold Bausch Health Companies company stock in the last year include Christina Ackermann and Mark C Mckenna. View Insider Buying and Selling for Bausch Health Companies.

Which major investors are buying Bausch Health Companies stock?

BHC stock was acquired by a variety of institutional investors in the last quarter, including Commerzbank Aktiengesellschaft FI, Academy Capital Management Inc. TX, Ardevora Asset Management LLP, Gabelli Funds LLC, Alberta Investment Management Corp, Nisa Investment Advisors LLC, Fox Run Management L.L.C. and Cambridge Investment Research Advisors Inc.. Company insiders that have bought Bausch Health Companies stock in the last two years include John Paulson, Joseph C Papa, Paul Herendeen, Schutter Richard U De, Thomas Appio and William D Humphries. View Insider Buying and Selling for Bausch Health Companies.

How do I buy shares of Bausch Health Companies?

Shares of BHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Bausch Health Companies' stock price today?

One share of BHC stock can currently be purchased for approximately $28.48.

How big of a company is Bausch Health Companies?

Bausch Health Companies has a market capitalization of $10.02 billion and generates $8.38 billion in revenue each year. The company earns $-4,148,000,000.00 in net income (profit) each year or $4.02 on an earnings per share basis. Bausch Health Companies employs 21,100 workers across the globe.View Additional Information About Bausch Health Companies.

What is Bausch Health Companies' official website?

The official website for Bausch Health Companies is http://www.bauschhealth.com/.

How can I contact Bausch Health Companies?

Bausch Health Companies' mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The company can be reached via phone at 514-744-6792 or via email at [email protected]


MarketBeat Community Rating for Bausch Health Companies (NYSE BHC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  263 (Vote Outperform)
Underperform Votes:  291 (Vote Underperform)
Total Votes:  554
MarketBeat's community ratings are surveys of what our community members think about Bausch Health Companies and other stocks. Vote "Outperform" if you believe BHC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BHC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel